BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37690180)

  • 21. Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population.
    Jongbloed M; Bartolomeo V; Steens M; Dursun S; van de Lisdonk T; De Ruysscher DKM; Hendriks LEL
    Eur J Cancer; 2023 Sep; 190():112947. PubMed ID: 37451182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Radiotherapy for oligometastatic non-small cell lung cancer patients].
    Levy A; Roux C; Mercier O; Issard J; Botticella A; Barlesi F; Le Péchoux C
    Cancer Radiother; 2021 Oct; 25(6-7):517-522. PubMed ID: 34175225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oligometastatic non-small cell lung cancer: a narrative review of stereotactic ablative radiotherapy.
    Dohopolski M; Iyengar P
    Ann Palliat Med; 2021 May; 10(5):5944-5953. PubMed ID: 33691460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy.
    Miyawaki T; Wakuda K; Kenmotsu H; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ono A; Naito T; Murakami H; Notsu A; Mori K; Harada H; Endo M; Ohde Y; Takahashi K; Takahashi T
    Cancer Sci; 2021 Jan; 112(1):359-368. PubMed ID: 33098119
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
    Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
    Front Oncol; 2020; 10():987. PubMed ID: 32676455
    [No Abstract]   [Full Text] [Related]  

  • 27. Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature.
    Schanne DH; Heitmann J; Guckenberger M; Andratschke NHJ
    Cancer Treat Rev; 2019 Nov; 80():101892. PubMed ID: 31522079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer.
    Guerrero E; Ahmed M
    Lung Cancer; 2016 Feb; 92():22-8. PubMed ID: 26775592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
    Ashworth A; Rodrigues G; Boldt G; Palma D
    Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolving role of radiotherapy in treatment of oligometastatic NSCLC.
    Bergsma DP; Salama JK; Singh DP; Chmura SJ; Milano MT
    Expert Rev Anticancer Ther; 2015; 15(12):1459-71. PubMed ID: 26536370
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Bahig H; Tonneau M; Blais N; Wong P; Filion E; Campeau MP; Vu T; Al-Saleh A; Tehfé M; Florescu M; Roberge D; Masucci L; Richard C; Menard C; Routy B
    Clin Transl Radiat Oncol; 2022 Mar; 33():115-119. PubMed ID: 35243022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
    Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer: Theory and Practice.
    Rusthoven CG; Yeh N; Gaspar LE
    Cancer J; 2015; 21(5):404-12. PubMed ID: 26389766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival.
    Chang JY; Verma V
    J Natl Compr Canc Netw; 2022 May; 20(5):531-539. PubMed ID: 35545175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
    Chan OSH; Lam KC; Li JYC; Choi FPT; Wong CYH; Chang ATY; Mo FKF; Wang K; Yeung RMW; Mok TSK
    Lung Cancer; 2020 Apr; 142():41-46. PubMed ID: 32088604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
    Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
    Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.
    Amini A; Verma V; Simone CB; Chetty IJ; Chun SG; Donington J; Edelman MJ; Higgins KA; Kestin LL; Movsas B; Rodrigues GB; Rosenzweig KE; Rybkin II; Slotman BJ; Wolf A; Chang JY
    Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):361-375. PubMed ID: 34571054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.